Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes
EuroIntervention · 2023-03 · 18 (15) · 1244-1253
DOI: 10.4244/eij-d-22-00654 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2023-03. Verfasst von Anoop N Koshy und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Myocardial Infarction, Acute Coronary Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Potent P2Y12 inhibitors such as ticagrelor and prasugrel are superior to clopidogrel in acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI). Whether this benefit extends to a patient population with chronic coronary syndromes (CCS) is unclear. AIMS: We sought to compare the safety and efficacy of prasugrel and ticagrelor versus clopidogrel in patients undergoing PCI for CCS. METHODS: Consecutive patients undergoing PCI for CCS at a tertiary centre between 2014 and 2019 who were discharged on prasugrel or ticagrelor were compared with those on clopidogrel. The primary endpoint was the composite of death and myocardial infarction (MI), with secondary outcomes including rates of bleeding, stroke, and target vessel revascularisation at 1 year. RESULTS: Overall, 11,508 patients were included in the study (ticagrelor/prasugrel n=2,860 [24.9%], clopidogrel n=8,648 [75.1%]) with an increasing frequency of potent P2Y12 inhibitor use over the study period (ptrend
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Cardiology, Austin Health, The University of Melbourne, Melbourne, Australia.
- Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zitieren
APA
Koshy, A. N., Giustino, G., Sartori, S., Hooda, A., Feng, Y., Snyder, C., Dasgupta, S., Kumar, K. R., Krishnamoorthy-Melarcode, P., Sweeny, J., Khera, S., Serrao, G. W., Sharma, R., Dangas, G., Kini, A. S., Mehran, R., & Sharma, S. K. (2023). Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention, 18(15), 1244-1253. https://doi.org/10.4244/eij-d-22-00654
Vancouver
Koshy AN, Giustino G, Sartori S, Hooda A, Feng Y, Snyder C, et al. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. EuroIntervention. 2023;18(15):1244-1253. doi:10.4244/eij-d-22-00654
BibTeX
@article{Koshy2023,
author = {Koshy, Anoop N and Giustino, Gennaro and Sartori, Samantha and Hooda, Amit and Feng, Yihan and Snyder, Clayton and Dasgupta, Shabitri and Kumar, Kartik R and Krishnamoorthy-Melarcode, Parasuram and Sweeny, Joseph and Khera, Sahil and Serrao, Gregory W and Sharma, Raman and Dangas, George and Kini, Annapoorna S and Mehran, Roxana and Sharma, Samin K},
title = {Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes},
journal = {EuroIntervention},
year = {2023},
volume = {18},
number = {15},
pages = {1244--1253},
doi = {10.4244/eij-d-22-00654}
}
EUVIMED